Performance
LowHasn't faired well - amongst the low performers
Valuation
HighSeems to be overvalued vs the market average
Growth
AvgFinancials growth has been moderate for a few years
Profitability
HighShowing good signs of profitability & efficiency
Entry point
GoodThe stock is underpriced and is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
PE RatioPE Ratio | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
17.37 | 3.45 | 0.58% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
34.15 | 4.18 | 0.92% |
Caplin Point Laboratories Limited is a pharmaceutical company. The Company's product segments include Antibiotics, Non-steroidal anti-inflammatory drugs (NSAIDS), Ophthalmics, Pain Management and Anti-ulcers.
Customise key metrics, see detailed forecasts, download stock data and more
Pledged promoter holdings is insignificant
In last 3 months, mutual fund holding of the company has almost stayed constant
CAPLIN POINT LABORATORIES LIMITEDhas informed the Exchange about Board Meeting to be held on 11-Feb-2023to inter-alia consider and approve the Unaudited financial results of the Company for the Quarterly ended December 2022 . | Download
CAPLIN POINT LABORATORIES LIMITEDhas informed the Exchange about Board Meeting to be held on 11-Feb-2023to inter-alia consider and approve the Unaudited financial results of the Company for the Quarterly ended December 2022 . | Download
Final • Div/Share: ₹ 2
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant